Elevated Insulin-Like Growth Factor-1-Induced Female Rats Perpetuate the Polycystic Ovary Syndrome Phenotype: Pathological Mechanism of Insulin-Like Growth Factor-1 in Polycystic Ovary Syndrome

Objectives: This study was designated to establish a polycystic ovary syndrome (PCOS) rat model with recombinant human insulin-like growth factor-1 (RH-IGF-1). We made assessment on the characteristics of hyperinsulinemia and hyperandrogenism in the rat model. Design: This study performed the characteristics of PCOS upon RH-IGF-1 injection and evaluated the disease process of PCOS syndrome caused by the insulin-resistant pathological condition of IGF-1 based on the comparative study of in vivo test. Setting: The experiment was conducted in the experimental research center of Yinzhou NO.2 hospital, Ningbo, Zhejiang Province, China. Materials and Methods: Thirty-four female Sprague Dawley immature rats aged 21 days were randomly divided into two groups. Those treated with RH-IGF-1 2 mg/100 g daily were in RH-IGF-1 group (n = 20), and those with 0.9% sodium chloride 0.2 mL/100 g daily were in the saline group (n = 14). The experiment was carried out in two stages. In stage I, rats were anesthetized upon the first estrous cycle in the saline group with tissue and blood samples collected (n = 7), and rats in the RH-IGF-1-treated group were anesthetized on the 5th day after vaginal opening (VO) (n = 10). In stage II, rats in the saline group were anesthetized after three complete cycles (n = 7), meanwhile, while on the 15th day after VO (n = 10) for those in the RH-IGF-1 group. Results: We have found that compared with the control group, rats injected with RH-IGF-1 expressed an early VO, disordered estrous cycle, polycystic ovaries, and significantly increased ovarian weight/body weight ratio. And from the perspective of hormone secretion, their androgen increased significantly and the insulin resistance index also elevated distinctly, possessing main characteristics similar to PCOS. Limitations: In this study, we were limited by the inability to examine IGF-1 in hypothalamus. IGF-1 in hypothalamus and in vitro experiments would be taken into consideration for further study in the future. Conclusions: These findings suggest that IGF-1 may be a key factor in the pathogenesis of PCOS, and the increase of androgen may be the pathological result, not the cause of PCOS.

[1]  G. Bifulco,et al.  Microbiome and PCOS: State-of-Art and Future Aspects , 2021, International journal of molecular sciences.

[2]  G. Franci,et al.  Polycystic Ovary Syndrome and Probiotics: A Natural Approach to an Inflammatory Disease , 2021, Current Women s Health Reviews.

[3]  M. Poutanen,et al.  Metabolic regulation of female puberty via hypothalamic AMPK–kisspeptin signaling , 2018, Proceedings of the National Academy of Sciences.

[4]  Hyun-Seok Jin,et al.  High Genetic Risk Scores of ASIC2, MACROD2, CHRM3, and C2orf83 Genetic Variants Associated with Polycystic Ovary Syndrome Impair Insulin Sensitivity and Interact with Energy Intake in Korean Women , 2018, Gynecologic and Obstetric Investigation.

[5]  D. Romero,et al.  Long-Lasting Androgen-Induced Cardiometabolic Effects in Polycystic Ovary Syndrome , 2018, Journal of the Endocrine Society.

[6]  S. Mumford,et al.  Maternal polycystic ovarian syndrome and early offspring development , 2018, Human Reproduction.

[7]  David Handelsman,et al.  Evidence from animal models on the pathogenesis of PCOS. , 2018, Best practice & research. Clinical endocrinology & metabolism.

[8]  S. Aydın,et al.  Clinical and metabolic characteristics of Turkish adolescents with polycystic ovary syndrome , 2018, Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology.

[9]  F. Tehrani,et al.  Hormone‐induced rat model of polycystic ovary syndrome: A systematic review , 2017, Life sciences.

[10]  Brian K. Lee,et al.  Maternal polycystic ovary syndrome and the risk of autism spectrum disorders in the offspring: a population-based nationwide study in Sweden , 2015, Molecular Psychiatry.

[11]  R. Voutilainen,et al.  Premature adrenarche: Etiology, clinical findings, and consequences , 2015, The Journal of Steroid Biochemistry and Molecular Biology.

[12]  Xin Li,et al.  PCOS and obesity: insulin resistance might be a common etiology for the development of type I endometrial carcinoma. , 2014, American journal of cancer research.

[13]  V. Padmanabhan,et al.  Sheep models of polycystic ovary syndrome phenotype , 2013, Molecular and Cellular Endocrinology.

[14]  D. Vine,et al.  Animal models of polycystic ovary syndrome: a focused review of rodent models in relationship to clinical phenotypes and cardiometabolic risk. , 2012, Fertility and sterility.

[15]  D. Dunger,et al.  Higher Levels of IGF-I and Adrenal Androgens at Age 8 Years Are Associated with Earlier Age at Menarche in Girls , 2012, The Journal of clinical endocrinology and metabolism.

[16]  Ricardo Azziz,et al.  Polycystic ovary syndrome: etiology, pathogenesis and diagnosis , 2011, Nature Reviews Endocrinology.

[17]  A. Bremer.  Polycystic ovary syndrome in the pediatric population. , 2010, Metabolic syndrome and related disorders.

[18]  L. Tatò,et al.  Prevalence of polycystic ovary syndrome in young women who had idiopathic central precocious puberty. , 2010, Fertility and sterility.

[19]  R. Norman,et al.  The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. , 2009, Fertility and sterility.

[20]  R. Rosenfield.  Clinical review: Identifying children at risk for polycystic ovary syndrome. , 2007, The Journal of clinical endocrinology and metabolism.

[21]  E. Kousta.  Premature Adrenarche Leads to Polycystic Ovary Syndrome? , 2006, Annals of the New York Academy of Sciences.

[22]  Krishna B. Singh.  Persistent estrus rat models of polycystic ovary disease: an update. , 2005, Fertility and sterility.

[23]  H. Zisser,et al.  Screening for and Treatment of Polycystic Ovary Syndrome in Teenagers , 2004, Experimental biology and medicine.

[24]  L. Ibáñez,et al.  Premature adrenarche--normal variant or forerunner of adult disease? , 2000, Endocrine reviews.

[25]  P. Saenger,et al.  The roles of insulin sensitivity, insulin-like growth factor I (IGF-I), and IGF-binding protein-1 and -3 in the hyperandrogenism of African-American and Caribbean Hispanic girls with premature adrenarche. , 1999, The Journal of clinical endocrinology and metabolism.

[26]  W. Miller,et al.  The Regulation of Human P450c17 Activity: Relationship to Premature Adrenarche, Insulin Resistance and the Polycystic Ovary Syndrome , 1998, Trends in Endocrinology & Metabolism.

[27]  J. Dimartino-Nardi.  Insulin Resistance in Prepubertal African–American and Hispanic Girls with Premature Adrenarche: A Risk Factor for Polycystic Ovary Syndrome , 1998, Trends in Endocrinology & Metabolism.

[28]  Anin,et al.  Development of hyperandrogenism during treatment with insulin‐like growth factor‐I (IGF‐I) in female patients with Laron syndrome , 1998, Clinical endocrinology.

[29]  M. C. Andrews.  Bilateral polycystic ovaries associated with sterility, amenorrhea and hirsutism. , 1953, Virginia medical monthly.

[30]  E. Otto-Buczkowska,et al.  Polycystic ovary syndrome (PCOS) and the accompanying disorders of glucose homeostasis among girls at the time of puberty. , 2018, Pediatric endocrinology, diabetes, and metabolism.

[31]  T. Delibaşı,et al.  Insulin-like growth factor 1, liver enzymes, and insulin resistance in patients with PCOS and hirsutism. , 2014, Turkish journal of medical sciences.

[32]  D. McMahon,et al.  Elevated free IGF-I levels in prepubertal Hispanic girls with premature adrenarche: relationship with hyperandrogenism and insulin sensitivity. , 2002, The Journal of clinical endocrinology and metabolism.